We have identified three families of compounds that have a very strong affinity for the GR_II receptor, (“selective GR-II antagonists”). We hope that selective GR-II antagonists will have the metabolic, psychiatric and other benefits of mifepristone without causing termination of pregnancy. Like mifepristone, these are non-steroidal small molecules. Corcept owns world-wide rights to these compounds through composition of matter and other patents that extend through 2030.